COMP <GO>
TRLV vs DFTX // ALTMAN Z-SCORE & DEBT/EQUITY
Trulieve Cannabis Corp. Subordinate Voting Shares (NYSE) VS. Definium Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: TRLV 5
— DFTX 4
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: DFTX
LAST: $10.28 (-3.02%) • MKT CAP: $2.04B
balance-sheet
1.12
LAST: $36.33 (-4.29%) • MKT CAP: $5.10B
balance-sheet
26.00
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TRLV VS. DFTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TRLV | DFTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 60.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.80% | -32.20% | +45.00 | TRLV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 9.9x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 11.20% | -3.84% | +15.04 | TRLV | /fcf-yield <GO> |
| Operating Margin | 12.10% | -11.60% | +23.70 | TRLV | /operating-margins <GO> |
| Net Profit Margin | -9.90% | -12.90% | +3.00 | TRLV | /net-margins <GO> |
| Revenue Growth (YoY) | -0.40% | 5.50% | -5.90 | DFTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 1.12 | 26.00 | -24.88 | DFTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 5/9 | +1.00 | TRLV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.3 | 55.4 | -7.10 | DFTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 33.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.04B | $5.10B | -$3.06B | DFTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TRLV REV | DFTX REV | TRLV GROSS % | DFTX GROSS % | TRLV FCF | DFTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.18B | $0 | 60.2% | — | $228.6M | -$131.6M |
| FY 2024 | $1.19B | $0 | 60.3% | — | $148.9M | -$79.1M |
| FY 2023 | $1.13B | $0 | — | — | $201.8M | -$64.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TRLV // BETA —
DFTX // BETA 1.08